Optometry Times

Optometry Times

National, Trade/B2B
English
Magazine

Outlet metrics

Domain Authority
45
Ranking

Global

#620291

United States

#310017

Health/Health

#5531

Traffic sources
Monthly visitors

Articles

  • 1 week ago | optometrytimes.com | Sydney M Crago |Modern Retina |Emily Kaiser Maharjan

    The FDA has granted 510(k) clearance to BVI Medical for its glaucoma surgical system, called Leos (Laser Endoscopy Ophthalmic System). Leos is designed to introduce a novel, intuitive Laser ECP procedure that can integrate seamlessly into the surgical workflow. Notably this is the only laser system that lowers intraocular pressure by addressing aqueous humor production in a minimally invasive ab interno procedure.

  • 1 week ago | optometrytimes.com | Jordana Joy

    The Ohio State University (OSU) College of Optometry has awarded CooperVision its Neal J. Bailey Optometry Medal for Development.1 The award was presented at OSU’s 2025 Visionary Appreciation Event and recognizes the company for its support of educational opportunities for students, including the funding for a new eye care clinic, according to a news release.

  • 1 week ago | optometrytimes.com | Jordana Joy

    April 15, 2025By The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.

  • 1 week ago | optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan

    The landscape of myopia management is evolving rapidly, with growing global awareness and an increasing arsenal of treatment options. In a recent discussion on the FDA's acceptance of Sydnexis's NDA submission for SYD-101, a non-compounded atropine drop indicated for myopia, Paul Karpecki, OD, FAAO, emphasized how the perception of myopia has shifted—from a benign refractive error to a serious medical condition with long-term ocular health implications.

  • 1 week ago | optometrytimes.com | Sydney M Crago |Modern Retina

    Oculis Holdings has completed enrollment in both Phase 3 DIAMOND-1 (NCT05066997) and DIAMOND-2 (NCT06172257) trials. These trials are investigating the company’s OCS-01 eye drops for the treatment of diabetic macular degeneration (DME) and are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the US Food and Drug Administration (FDA).

Optometry Times journalists

Contact details

Address

123 Example Street

City, Country 12345

Phone

+1 (555) 123-4567

Email Patterns

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations